Objective: To evaluate real-world treatment patterns and adherence to deutetrabenazine (DTBZ) in patients with Huntington’s disease (HD) or tardive dyskinesia (TD).
Background: DTBZ is a vesicular monoamine transporter 2 inhibitor approved for the treatment of chorea associated with HD and for TD in adults. DTBZ is titrated from a starting dose of 6 mg/day in HD and 12 mg/day in TD at weekly intervals of 6 mg/day to a maximum of 48 mg/day based on dyskinesia control and tolerability.
Method: Insurance claims data from the Symphony Health Solutions Integrated Dataverse (May 2017–May 2019) were retrospectively analyzed for patients with a diagnosis of HD or TD and ≥1 DTBZ prescription. All eligible patients were included in treatment pattern analyses that included achievement of a stable DTBZ dose, defined as the first average daily dose that remained constant for ≥60 days after an initial 30-day period that may have included dose titration. For patients who continued treatment after 30 days, adherence was measured as the proportion of patients with more than 80% of days covered (PDC >80%).
Results: The DTBZ treatment pattern analyses included 363 patients with HD and 505 patients with TD; of these patients, 273 with HD and 350 with TD were included in the adherence analyses. Among patients with HD and TD, respectively, 53.7% (195/363) and 47.5% (240/505) reached a stable dose of DTBZ. The mean (SD) average daily stable dose was 28.5 (14.1) mg for patients with HD and 25.6 (12.4) mg for patients with TD. The most commonly used stable daily doses were 24 mg (27.2%) and 48 mg (21.5%) among patients with HD. More than one-third (37.5%) of patients with TD had a stable dose of 24 mg/day. From the end of the initial 30-day dosing period to month 6, 64.1% of patients with HD and 53.4% of patients with TD were adherent to DTBZ. Mean (SD) PDC at 6 months was 78.6% (26.5%) for patients with HD and 70.8% (29.4%) for patients with TD.
Conclusion: This study provides real-world evidence that most patients who continue treatment after an initial 30-day period remain adherent through 6 months. Research is needed to determine how adherence is affected by DTBZ dosing patterns and patient characteristics.
To cite this abstract in AMA style:R. Ayyagari, A. Wilhelm, J. Alexander, N. Chaijale, V. Garcia-Horton, F. Devine, B. Carroll. Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington’s Disease or Tardive Dyskinesia [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/real-world-deutetrabenazine-dosing-patterns-in-patients-with-huntingtons-disease-or-tardive-dyskinesia/. Accessed December 5, 2023.
« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/real-world-deutetrabenazine-dosing-patterns-in-patients-with-huntingtons-disease-or-tardive-dyskinesia/